{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:03:36Z","timestamp":1784765016622,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:03:29Z","timestamp":1779912209000},"page":"701-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Francesca","family":"Bolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2026.04.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2018.10.015","article-title":"The immunobiology of female predominance in primary biliary cholangitis","volume":"95","author":"Gerussi","year":"2018","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.cld.2026.04.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2026.04.003_bib3","doi-asserted-by":"crossref","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a U.S. community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.003_bib4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.21953","article-title":"Quality of life and everyday activities in patients with primary biliary cirrhosis","volume":"46","author":"Selmi","year":"2007","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","article-title":"Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis","volume":"6","author":"Hollingsworth","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.003_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.003_bib8","series-title":"Autoimmune liver disease - management and clinical practice","author":"James Neuberger","year":"2020"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib9","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib10","article-title":"Primary biliary cirrhosis and liver transplantation","volume":"1","author":"Akamatsu","year":"2012","journal-title":"Intractable Rare Dis Res"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2026.04.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2024.10.020","article-title":"Noninvasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis","volume":"23","author":"Calvaruso","year":"2025","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.003_bib15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib17","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.003_bib19","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2026.04.003_bib20","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002128","article-title":"Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis","volume":"118","author":"De Veer","year":"2023","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2026.04.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib22","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.09.062","article-title":"Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists","volume":"16","author":"Webb","year":"2018","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2026.04.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: a systematic review and meta-analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Digestive and Liver Disease"},{"issue":"7","key":"10.1016\/j.cld.2026.04.003_bib26","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.003_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","article-title":"Primary biliary cholangitis: personalizing second-line therapies","volume":"82","author":"Levy","year":"2025","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2026.04.003_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15386","article-title":"Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid","volume":"42","author":"De Vincentis","year":"2022","journal-title":"Liver International"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.003_bib32","series-title":"Autoimmune liver diseases: perspectives from Japan","article-title":"Bezafibrate treatment of primary Biliary cirrhosis","author":"Iwasaki","year":"2014"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib33","doi-asserted-by":"crossref","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.cld.2026.04.003_bib35","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.cld.2026.04.003_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.cld.2026.04.003_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.cld.2026.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","author":"Carbone","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.04.003_bib41","article-title":"Study on golexanolone for patients with primary biliary cholangitis experiencing fatigue and cognitive dysfunction","author":"Umecrine Cognition","year":"2025","journal-title":"European Clinical Trials Information Network (ClinicalTrials.eu)"},{"issue":"4","key":"10.1016\/j.cld.2026.04.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2022.06.014","article-title":"Liver transplantation for primary biliary cholangitis","volume":"26","author":"Martin","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2026.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.cld.2026.04.003_bib44","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-023-01979-1","article-title":"New therapies on the horizon for primary biliary cholangitis","volume":"84","author":"Tanaka","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.cld.2026.04.003_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100917","article-title":"Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice","volume":"6","author":"Kunst","year":"2024","journal-title":"JHEP Reports"},{"issue":"1","key":"10.1016\/j.cld.2026.04.003_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:36:11Z","timestamp":1784763371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000371"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}